Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript

Valter Pinto

Good afternoon, everyone, and welcome to the Intelligent Bio Solutions fireside chat. Thank you all for joining us today. My name is Valter Pinto, Managing Director at KCSA Strategic Communications. And today, I’m joined by Harry Simeonidis, President and CEO; and Peter Passaris, Vice President of Product Development. Earlier this month, the company submitted its 510(k) premarket notification package to the FDA for its intelligent Fingerprinting Drug Screening System, seeking clearance from the FDA to enter the U.S. market.

We’re hosting today’s call for management to have an opportunity to provide investors with more detail as to where we stand in the FDA process, more information regarding the data submitted to the FDA and provide a look ahead as to what to expect next. Before we begin, quickly, I’d like to remind everyone that statements made during today’s fireside chat may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company’s business, I refer you to the company’s reports filed periodically with the SEC, including its annual report on Form 10-K and for the fiscal year ended June 30, 2026, and the investor materials under the company’s Investor Relations website.

The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. I want to thank